摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R)-3-(carboxymethylsulfanyl)-2-methylpropanoic acid

中文名称
——
中文别名
——
英文名称
(2R)-3-(carboxymethylsulfanyl)-2-methylpropanoic acid
英文别名
——
(2R)-3-(carboxymethylsulfanyl)-2-methylpropanoic acid化学式
CAS
——
化学式
C6H10O4S
mdl
——
分子量
178.21
InChiKey
CEUSXEBEKZCYSJ-BYPYZUCNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    11
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    99.9
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • [EN] CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF<br/>[FR] CONJUGUÉ COMPRENANT UN LIGAND DE RÉCEPTEUR DE NEUROTENSINE ET SON UTILISATION
    申请人:3B PHARMACEUTICALS GMBH
    公开号:WO2015188934A1
    公开(公告)日:2015-12-17
    The present invention is related to a conjugate comprising a structure of general formula (1) [TM1] - [AD1] - [LM] - [AD2] - [TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK' is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (3) wherein ALK' is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.
查看更多